Departure of Directors or Certain

On April 17, 2017, ProPhase Labs, Inc. (the Company) entered into an Employment Agreement Termination and Release Agreement (the New Agreement) with Robert V. Cuddihy, Jr., the Companys Chief Operating Officer and Chief Financial Officer. The New Agreement terminates Mr. Cuddihys prior employment agreement with the Company (the Prior Agreement), and sets forth the new terms of Mr. Cuddihys employment with the Company. The New Agreement was entered into in view of the Companys recent successful sale of its Cold-EEZE

brand.

The terms of the New Agreement provide, among other things, that Mr. Cuddihy will remain employed by the Company on an at-will basis as the Companys Chief Financial Officer/Chief Accounting Officer; he will cease services as Chief Operatin g Officer of the Company but will become Chief Operating Officer/Contract Manufacturing and will focus on operational responsibility for the Companys manufacturing business; he will relinquish his rights under the Prior Agreement, including his rights to separation payments, in consideration for the Company remitting to him a $675,000 termination payment (the Termination Payment); he will receive an annual base salary of $350,000 until July 1, 2017, at which time his annual base salary will be reduced to $250,000. Mr. Cuddihy will also remain eligible to participate in the Companys equity incentive compensation plans, annual bonus plans, and employee benefit plans. He will also be entitled to receive four weeks paid vacation and a $1,250 monthly auto allowance. All of the arrangements with Mr. Cuddihy have been approved by the compensation committee of the Companys board of directors.

Pursuant to the terms of the New Agreement, in the event Mr. Cuddihys employment is terminated by the Company without Cause (as defined in the Agreement), Mr. Cuddihy will be entitled to receive a lump sum cash payment, in an amount equal to three months of his base salary then in effect, and all other accrued and vested but unpaid compensation through the date his employment is terminated, within two days of such date; provided, however, that in lieu of the severance payment, the Company, in its sole discretion, may instead provide Mr. Cuddihy a minimum of three months prior notice of termination.

The payments described in the New Agreement are subject to Mr. Cuddihys execution of a general release of claims in favor of the Company. In addition, in accordance with applicable law, Mr. Cuddihy is entitled to revoke his acceptance of the New Agreement within seven days of its execution. If he revokes his acceptance, the New Agreement will be of no further force or effect and Mr. Cuddihy will not be entitled to the benefits described above. If he does not revoke his acceptance, the New Agreement will be effective as of the eighth day after signing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

No.

Description

10.1

Employment Agreement Termination and Release Agreement

Pursuant to the requirements of the Securities Exchange Act of 1934, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ProPhase Labs, Inc.

By:

/s/ Ted Karkus

Ted Karkus

Chairman of the Board, Chief Executive Officer and Director

Date: April 19, 2017

Exhibits Index

No.

Description

10.1

Employment Agreement Termination and Release Agreement

makes a similar move, sign up!

Other recent filings from the company include the following:

ProPhase Labs's Chief Financial Officer just picked up 360,000 shares - Sept. 15, 2017
Tender offer statement by Issuer - Aug. 25, 2017

Auto Refresh

Feedback